+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RALT specifically halts maladaptive cardiac hypertrophy: a new kid on the block

RALT specifically halts maladaptive cardiac hypertrophy: a new kid on the block

Hypertension 53(3): 454-455

(PDF emailed within 0-6 h: $19.90)

Accession: 055333066

Download citation: RISBibTeXText

PMID: 19204178

DOI: 10.1161/HYPERTENSIONAHA.108.125930

Related references

P38 MAPK inhibition halts hypertensive end organ damage and premature mortality in a rat model of cardiac hypertrophy and dysfunction. European Heart Journal 22(Abstract Supplement): 31, September, 2001

Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 55(4): 939-945, 2010

Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. Febs Journal 272(11): 2684-2695, 2005

Time-warped comparison of gene expression in adaptive and maladaptive cardiac hypertrophy. Circulation. Cardiovascular Genetics 2(2): 116-124, 2010

Interleukin-18 knockout mice display maladaptive cardiac hypertrophy in response to pressure overload. Biochemical and Biophysical Research Communications 354(2): 552-558, 2007

Adaptive and maladaptive cardiac hypertrophy: what is the effective role of heat shock transcription factor 1?. Circulation Research 100(3): E45-E46, 2007

Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. Biochemical and Biophysical Research Communications 444(3): 332-337, 2014

Cardioprotection of exogenous erythropoietin in mice with ligature-induced aortic stenosis: effects on maladaptive cardiac hypertrophy. Journal of Physiology and Pharmacology 61(1): 13-20, 2010

Possible role of calcineurin in etiology of maladaptive cardiac hypertrophy in familial hypertrophic cardiomyopathy caused by missense sarcomeric mutations. Journal of the American College of Cardiology 35(2 suppl A): 201A, 2000

Molecular determinants of myocardial hypertrophy and failure: Alternative pathways for beneficial and maladaptive hypertrophy. European Heart Journal 24(10): 883-896, 2003

Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived stem cell therapy on regional remodeling measured by cardiac MRI. Clinical Research in Cardiology 100(11): 983-992, 2012

New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling. Journal of Biological Chemistry 288(25): 18335-18344, 2013

Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clinical and Experimental Hypertension. Part A, Theory and Practice 11(7): 1325-1350, 1989

Cyclosporin A does not block exercise-induced cardiac hypertrophy. Medicine and Science in Sports and Exercise 34(8): 1249-1254, 2002